Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

3 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Yesterday
The monoclonal antibody abrilumab is effective for treating moderate-to-severe ulcerative colitis, promoting remission, clinical response and mucosal healing, a recent study has found.

Initial cytoreductive nephrectomy prolongs OS in metastatic renal cell carcinoma

15 Dec 2017

Initial cytoreductive nephrectomy (CN) provides overall survival (OS) advantage in metastatic renal cell carcinoma (mRCC) compared with initial systemic therapy, a recent study reports.

Drawing data from the Surveillance, Epidemiology and End Results registries, researchers looked at 537 elderly patients (>65 years of age) with mRCC. They conducted sequential survival analysis to evaluate the effect of initial CN on OS, as well as instrumental variable analysis to account for measured and unmeasured selection bias.

Of the patients, 190 underwent initial CN followed by targeted therapy and 347 received initial targeted therapy.

Median OS was 17.4 months (IQR, 9.8 to 32.0) in the initial CN group compared with 9.2 months (IQR 4.3 to 18.0) in the initial targeted therapy group. On Cox proportional hazards analysis, initial CN improved OS by 50 percent (95 percent CI, 0.38 to 0.65). Propensity score matching showed that initial CN was associated with a survival advantage of 5.8 months (1.9 to 9.7).

In an analysis accounting for confounding, only a trend toward improved survival with initial CN (hazard ratio, 0.29; 0.08 to 1.00) was observed.

The improved OS observed with initial CN notwithstanding, researchers noted that selection for CN in the contemporary mRCC era might be confounded by regional variation and influenced by provider uncertainty. They highlighted the need for prospective randomized controlled trials to definitively address this clinical conundrum.

Current consensus-based guidelines recommend CN in carefully selected mRCC patients with a disease that can be managed with surgical resection. This is based on high-level evidence of CN with cytokine therapy and supported by retrospective cohort studies of CN with contemporary therapies. [Eur Urol 2015;67:913-924; J Natl Compr Canc Netw 2015;13:151-159]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

3 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Yesterday
The monoclonal antibody abrilumab is effective for treating moderate-to-severe ulcerative colitis, promoting remission, clinical response and mucosal healing, a recent study has found.